Mitochondrial & Longevity · 2mg × 10 vials
Immune-modulating thymic peptide. Clinically studied in hepatitis, sepsis and as an oncology adjunct.
Thymosin Alpha-1 is a 28-amino-acid peptide produced naturally by the thymus, the organ in which T cells mature. With age, and especially during chronic infection, sepsis, cancer, and post-viral syndromes, thymic output declines and naive T-cell production falls. Thymosin Alpha-1 acts as a thymic replacement signal: it drives immature thymocytes through maturation into functional CD4+ and CD8+ T cells, activates natural killer cells and dendritic cells, and upregulates Toll-like receptor signalling (primarily TLR9 and TLR2) on antigen-presenting cells.
The net effect is a rebalancing of immune function. It pushes a depressed immune system toward a competent Th1-type response (cell-mediated, antiviral, antitumour) while simultaneously dampening the runaway inflammation seen in sepsis and cytokine storm. This bidirectional action is why the same molecule has been studied both in chronic viral hepatitis, where the immune response needs augmenting, and in sepsis and severe COVID-19, where it needs restraining. Thymosin Alpha-1 is approved as Zadaxin in more than 35 countries for hepatitis B and C and as a vaccine adjuvant, and is designated an orphan drug in the US for several indications; it has no US marketing approval.
What the published studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pmc.ncbi.nlm.nih.gov/articles/PMC2750086/) - comprehensive mechanism + clinical applications review by the discoverer of Tα1
Read study ↗PubMedCamerini & Garaci, Historical review on the discovery of thymosin alpha 1 (PMC4859321)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859321/) - discovery history, T-cell maturation mechanism, regulatory approvals across 35+ countries
Read study ↗PubMedThymosin alpha 1 therapy in chronic hepatitis B, meta-analysis (PMID 11737030)](https://pubmed.ncbi.nlm.nih.gov/11737030/) - HBV response rates ~25-40% sustained virologic response vs ~10-15% untreated controls
Read study ↗PubMedThymosin alpha 1 in HCV combination therapy (PMC3539291)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3539291/) - HCV combination data with interferon and ribavirin
Read study ↗PubMedLiu et al, Thymosin Alpha 1 reduces 28-day mortality in severe sepsis (PMID 23979484)](https://pubmed.ncbi.nlm.nih.gov/23979484/) - RCT, Tα1 reduced sepsis 28-day mortality from 35% to 26% (absolute reduction 9%, p=0.06 trending)
Read study ↗PubMedWei Liu et al, Thymosin alpha 1 reduces mortality in severe COVID-19 (Clin Infect Dis 2020, PMC7184460)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7184460/) - retrospective cohort, 76 severe COVID patients, Tα1 reduced 28-day mortality from 30% to 11%
Read study ↗Storage: refrigerated, ~14-28 days after reconstitution. Tα1 is more stable than BPC/TB but still degrades, don't keep a reconstituted vial past a month. Unreconstituted lyophilized powder is shelf-stable at room temp for short windows but should be refrigerated for long storage.